Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Obesity Medicine
•
General Endocrinology
•
Primary Care
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
https://pubmed.ncbi.nlm.nih.gov/38747476/
Related Questions
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?
Is it safe to prescribe Invokana or Metformin for patients taking Biktarvy?
Do you typically adjust pump settings for patients with diabetes who are on automated insulin pumps and fasting all day for religious reasons such as Ramadan?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
